IL276165B - A process for adjusting the glycan content level of a glycoprotein - Google Patents

A process for adjusting the glycan content level of a glycoprotein

Info

Publication number
IL276165B
IL276165B IL276165A IL27616520A IL276165B IL 276165 B IL276165 B IL 276165B IL 276165 A IL276165 A IL 276165A IL 27616520 A IL27616520 A IL 27616520A IL 276165 B IL276165 B IL 276165B
Authority
IL
Israel
Prior art keywords
cells
cell
perfusion
cell culture
recombinant protein
Prior art date
Application number
IL276165A
Other languages
English (en)
Hebrew (he)
Other versions
IL276165A (en
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL276165(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL276165A publication Critical patent/IL276165A/en
Publication of IL276165B publication Critical patent/IL276165B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL276165A 2014-12-01 2015-12-01 A process for adjusting the glycan content level of a glycoprotein IL276165B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Publications (2)

Publication Number Publication Date
IL276165A IL276165A (en) 2020-09-30
IL276165B true IL276165B (en) 2022-11-01

Family

ID=55024253

Family Applications (2)

Application Number Title Priority Date Filing Date
IL276165A IL276165B (en) 2014-12-01 2015-12-01 A process for adjusting the glycan content level of a glycoprotein
IL252569A IL252569B (en) 2014-12-01 2017-05-29 A process for adjusting the level of glycan content of a glycoprotein

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL252569A IL252569B (en) 2014-12-01 2017-05-29 A process for adjusting the level of glycan content of a glycoprotein

Country Status (22)

Country Link
US (5) US10167492B2 (cg-RX-API-DMAC7.html)
EP (2) EP3680344A1 (cg-RX-API-DMAC7.html)
JP (4) JP6698681B2 (cg-RX-API-DMAC7.html)
KR (1) KR102623965B1 (cg-RX-API-DMAC7.html)
CN (1) CN107109455B (cg-RX-API-DMAC7.html)
AU (5) AU2015355087C1 (cg-RX-API-DMAC7.html)
CA (1) CA2969225C (cg-RX-API-DMAC7.html)
CL (1) CL2017001369A1 (cg-RX-API-DMAC7.html)
CY (1) CY1123247T1 (cg-RX-API-DMAC7.html)
DK (1) DK3227454T3 (cg-RX-API-DMAC7.html)
EA (2) EA202091598A3 (cg-RX-API-DMAC7.html)
ES (1) ES2784503T3 (cg-RX-API-DMAC7.html)
HU (1) HUE049201T2 (cg-RX-API-DMAC7.html)
IL (2) IL276165B (cg-RX-API-DMAC7.html)
LT (1) LT3227454T (cg-RX-API-DMAC7.html)
MX (1) MX385409B (cg-RX-API-DMAC7.html)
PL (1) PL3227454T3 (cg-RX-API-DMAC7.html)
PT (1) PT3227454T (cg-RX-API-DMAC7.html)
SG (2) SG11201704351WA (cg-RX-API-DMAC7.html)
SI (1) SI3227454T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016089919A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201703729B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3680344A1 (en) 2014-12-01 2020-07-15 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
EP3397282A4 (en) 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. METHODS RELATING TO BIOLOGICA
EP3596225A1 (en) * 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN110520538B (zh) * 2017-03-31 2024-02-20 勃林格殷格翰国际公司 灌注培养基
CN111373028B (zh) * 2017-11-30 2022-07-05 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
CN112272708A (zh) * 2018-05-24 2021-01-26 阿雷斯贸易股份有限公司 控制糖蛋白组合物去岩藻糖基化水平的方法
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
AU2019339895A1 (en) 2018-09-11 2021-03-11 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
US11634499B2 (en) 2018-11-13 2023-04-25 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
CN113474366B (zh) 2018-12-31 2025-01-17 动量制药公司 产生优特克单抗的方法
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
US20220177580A1 (en) 2019-05-06 2022-06-09 Amgen Inc. Modulating antibody effector functions
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
EP4189064A1 (en) * 2020-07-30 2023-06-07 Amgen Inc. Cell culture media and methods of making and using the same
KR20230042125A (ko) * 2020-08-14 2023-03-27 브리스톨-마이어스 스큅 컴퍼니 단백질에 대한 제조 공정
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4413150A4 (en) * 2022-02-25 2025-09-10 Kashiv Biosciences Llc METHOD FOR ENHANCING POLYPEPTIDE EXPRESSION IN MAMMALIAN CELL CULTURE
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025036924A1 (en) * 2023-08-16 2025-02-20 Glaxosmithkline Intellectual Property Limited Method of controlling antibody glycosylation profile

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
MXPA02011534A (es) 2000-05-26 2004-08-12 Bristol Myers Squibb Co Moleculas mutantes ctla4 solubles y uso de las mismas.
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
ES2564790T5 (es) 2005-12-08 2023-08-25 Amgen Inc Producción mejorada de glicoproteínas usando manganeso
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
PE20081194A1 (es) 2006-07-13 2008-09-22 Wyeth Corp Produccion de glicoproteinas
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
AU2008232699A1 (en) * 2007-03-30 2008-10-09 Centocor Ortho Biotech Inc. High expression clones of mammalian cells with fluorescent protein A or G
AU2008240080A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
KR101307697B1 (ko) 2007-06-15 2013-09-11 암젠 인크 생물반응기에서 사용하기 위한 세포 배양 배지의 처리 방법
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
BR112013009275A2 (pt) 2010-10-20 2017-06-20 Morphotek Inc glicoformas de anticorpo alfa de receptor anti-folato
JP2014506482A (ja) 2011-02-23 2014-03-17 アムジエン・インコーポレーテツド Ｕｖｃ露光のための細胞培養培地およびそれに関連した方法
JP2014509850A (ja) * 2011-03-06 2014-04-24 メルク セロノ ソシエテ アノニム 低フコース細胞株およびその使用
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
LT2837680T (lt) * 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
JP2014526265A (ja) 2011-09-16 2014-10-06 アムジエン・インコーポレーテツド 細胞培養物のフィードバック制御を伴わない予めプログラムされた連続供給
CN104136047B (zh) 2011-10-26 2018-02-06 安姆根有限公司 减少或消除由暴露于uv光而引起的蛋白质修饰和降解的方法
CN104487570A (zh) * 2012-01-20 2015-04-01 新加坡科技研究局 Cho-gmt重组蛋白的表达
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
US10955291B2 (en) 2012-03-15 2021-03-23 Amgen Inc. Methods of determining exposure to UV light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
JP6273205B2 (ja) * 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
EA201690269A1 (ru) 2013-07-23 2016-05-31 Сентро Де Инмунологиа Молекулар Способы контроля уровней фукозилирования в белках
SI3110961T1 (sl) * 2014-02-27 2020-03-31 F. Hoffmann-La Roche Ag Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina
US20170321240A1 (en) * 2014-10-27 2017-11-09 Agency For Science, Technology And Research Glycosylation mutants for producing galactose-free and fucose-free polypeptides
EP3680344A1 (en) 2014-12-01 2020-07-15 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Also Published As

Publication number Publication date
AU2015355087B2 (en) 2020-04-09
AU2024204313A1 (en) 2024-07-11
ZA202006002B (en) 2022-03-30
JP2022101669A (ja) 2022-07-06
US10167492B2 (en) 2019-01-01
US20210017565A1 (en) 2021-01-21
PT3227454T (pt) 2020-04-06
PL3227454T3 (pl) 2020-07-27
EA036178B1 (ru) 2020-10-09
EA202091598A2 (ru) 2020-10-30
KR20170083636A (ko) 2017-07-18
JP2020124216A (ja) 2020-08-20
EP3227454B1 (en) 2020-01-29
EP3680344A1 (en) 2020-07-15
IL276165A (en) 2020-09-30
ZA201703729B (en) 2021-03-31
SI3227454T1 (sl) 2020-06-30
AU2015355087A1 (en) 2017-06-29
CY1123247T1 (el) 2021-10-29
JP2017538446A (ja) 2017-12-28
HUE049201T2 (hu) 2020-09-28
EP3227454A1 (en) 2017-10-11
JP6698681B2 (ja) 2020-05-27
EA201791223A1 (ru) 2017-10-31
US20190085370A1 (en) 2019-03-21
LT3227454T (lt) 2020-07-27
JP2024095777A (ja) 2024-07-10
US20200172947A1 (en) 2020-06-04
MX2017006997A (es) 2017-10-16
JP7066775B2 (ja) 2022-05-13
IL252569A0 (en) 2017-07-31
AU2025223948A1 (en) 2025-09-18
EA202091598A3 (ru) 2021-01-29
KR102623965B1 (ko) 2024-01-11
BR112017011652A2 (pt) 2018-06-26
WO2016089919A1 (en) 2016-06-09
US20230159974A1 (en) 2023-05-25
AU2022200586A1 (en) 2022-02-24
CL2017001369A1 (es) 2018-02-23
CA2969225A1 (en) 2016-06-09
US20170362625A1 (en) 2017-12-21
AU2020202302A1 (en) 2020-04-23
SG10202002458PA (en) 2020-04-29
CN107109455A (zh) 2017-08-29
CN107109455B (zh) 2022-02-18
MX385409B (es) 2025-03-04
SG11201704351WA (en) 2017-06-29
DK3227454T3 (da) 2020-04-14
CA2969225C (en) 2023-08-22
AU2015355087C1 (en) 2025-10-30
US10822630B2 (en) 2020-11-03
IL252569B (en) 2020-08-31
ES2784503T3 (es) 2020-09-28

Similar Documents

Publication Publication Date Title
US20230159974A1 (en) Process for manipulating the level of glycan content of a glycoprotein
US11427848B2 (en) Methods for harvesting mammalian cell cultures
HK40034016A (en) Process for manipulating the level of glycan content of a glycoprotein
HK40065682B (en) Methods for harvesting mammalian cell cultures
HK40065682A (en) Methods for harvesting mammalian cell cultures
BR112017011652B1 (pt) Método para manipulação do nível de teor de glicano fucosilado em uma proteína recombinante
HK40014805B (en) Methods for harvesting mammalian cell cultures
HK40014805A (en) Methods for harvesting mammalian cell cultures
HK1236575B (en) Methods for harvesting mammalian cell cultures
HK1236575A1 (en) Methods for harvesting mammalian cell cultures